<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00472823</url>
  </required_header>
  <id_info>
    <org_study_id>AG0081</org_study_id>
    <secondary_id>1R01AG028168-01</secondary_id>
    <nct_id>NCT00472823</nct_id>
  </id_info>
  <brief_title>Vitamin D Supplementation in Older Women</brief_title>
  <acronym>VIDOS</acronym>
  <official_title>Determination of RDA for Vitamin D in Caucasian and African American Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Creighton University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Office of Dietary Supplements (ODS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Nebraska</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Creighton University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the effects of several doses of vitamin D on hormones&#xD;
      related to bone, calcium absorption, bone density and muscle strength.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The prevalence of osteoporosis is high in the United States, with about 10 million people&#xD;
      over the age of 50 already having the disease and another 34 million at risk for developing&#xD;
      it. Development of low-cost and effective strategies is important for preventing osteoporosis&#xD;
      and reducing osteoporotic fractures. A simple inexpensive strategy to prevent osteoporosis is&#xD;
      adequate nutrition with calcium and vitamin D. Serum 25OHD (25-hydroxyvitamin D) is now&#xD;
      accepted as the objective measure of vitamin D nutrition. There is a growing understanding&#xD;
      that serum 25OHD concentrations of at least 30-32 ng/ml are needed for optimal bone health at&#xD;
      which serum parathyroid hormone (PTH) concentrations reach a minimum.&#xD;
&#xD;
      There are no systematic prospective dose response studies aimed at determining the optimum&#xD;
      amount of vitamin D intake required to maintain optimum serum 25OHD levels in the population&#xD;
      which will help in determining the estimated average requirement (EAR) and recommended&#xD;
      dietary requirement (RDA) for vitamin D. More work to determine the RDA for vitamin D has&#xD;
      been recommended by the Panel on Calcium and Related Nutrients of the Food and Nutrition&#xD;
      Board. This study is aimed at filling the information gap by concentrating on the high risk&#xD;
      group of postmenopausal women. We are testing the theory that increasing serum 25OHD to a&#xD;
      level greater than 30 ng/ml will reduce serum PTH in the high risk group of vitamin D&#xD;
      insufficient postmenopausal women with an adequate intake of calcium. We also believe that&#xD;
      the dose of vitamin D that will achieve this level is approximately 4400IU per day, which is&#xD;
      well above the suggested adequate intake of 400-600 ID recommended for the elderly.&#xD;
&#xD;
      In a one year double blind, randomized prospective clinical trial, we will examine the dose&#xD;
      response effect of supplementation with different doses of vitamin D3 (400, 800, 1600, 2400,&#xD;
      3200, 4000, 4800IU/day) on the primary outcomes of serum 25OHD and PTH in 160 postmenopausal&#xD;
      Caucasian and 160 African American women who have inadequate vitamin D levels in winter. We&#xD;
      expect that the results from this study will add useful and important information about the&#xD;
      RDA for vitamin D for postmenopausal women who are more susceptible to osteoporosis. The&#xD;
      results from this study will also help in designing future clinical trials to study the&#xD;
      effect of vitamin D, for example in preventing fractures, falls, cancer.&#xD;
&#xD;
      The main objective of the current proposal is to study the effect of increasing doses of&#xD;
      vitamin D3 in the high risk group of postmenopausal Caucasian and African American women with&#xD;
      hypovitaminosis D (serum 25OHD &lt;20 ng/ml) in winter in presence of sufficient calcium intake,&#xD;
      in order to determine the Estimated Average Requirement (EAR) that covers 50% and the&#xD;
      Recommended Daily allowance (RDA) covers 97.5% of population for vitamin D. We will use a&#xD;
      serum 25OHD concentration equal &gt;30 ng/ml and normalization of serum PTH as indicators of&#xD;
      adequacy. We expect that the results from this proposal will add important information&#xD;
      helpful in designing future larger clinical trials to determine the recommended dietary&#xD;
      allowance (RDA) for vitamin D in other ethnic groups and designing clinical trials on the&#xD;
      effect of vitamin D on falls and fractures.&#xD;
&#xD;
      We hypothesize that increasing serum 25OHD to a level greater than 30 ng/ml with vitamin D&#xD;
      supplements in 97 percent of the study subjects will reduce serum PTH and bone markers to&#xD;
      premenopausal range. We postulate that the RDA of vitamin D that will achieve a serum 25OHD&#xD;
      of â‰¥ 30 ng/ml in 97.5% of women during winter is approximately 4400 IU/d and the EAR dose of&#xD;
      vitamin D is between 800-1000 IU.&#xD;
&#xD;
      The specific aims of the proposal are,&#xD;
&#xD;
        1. To examine the dose response effect of vitamin D3, 400, 800, 1600, 2400, 3200, 4000, and&#xD;
           4800 IU /d in postmenopausal Caucasian and African American women with hypovitaminosis D&#xD;
           (serum 25OHD equal &lt;20 ng/ml) in winter plus an adequate calcium intake compared to a&#xD;
           calcium control group, on serum 25OHD and PTH levels, which constitute our primary&#xD;
           outcome measures.&#xD;
&#xD;
        2. To determine the EAR and RDA for postmenopausal women by establishing the dose of&#xD;
           vitamin D3 that will increase serum 25OHD above 30 ng/ml in 97.5% of study subjects in&#xD;
           winter and reduce serum PTH to the normal premenopausal range.&#xD;
&#xD;
        3. To study the dose response effect of vitamin D3 on calcium absorption,&#xD;
           1,25-dihydroxyvitamin D3 (1,25(OH)2D3) serum calcium, serum bone markers, bone mineral&#xD;
           density (BMD) and falls (only in elderly) (the secondary outcome measures)&#xD;
&#xD;
        4. To establish the long term safety of these doses relating to hypercalcemia and&#xD;
           hypercalciuria&#xD;
&#xD;
      Progress: Caucasian enrollment completed July 2008; African American enrollment completed May&#xD;
      2009&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Serum 25-hydroxyvitamin D (25OHD) and parathyroid hormone (PTH) levels</measure>
    <time_frame>Baseline, 6months,12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Calcium absorption</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>100mg calcium+ calcium45</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum/urine calcium</measure>
    <time_frame>Baseline and every 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone markers</measure>
    <time_frame>Baseline, and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone density</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>spine,hip,total body,lateral</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle strength</measure>
    <time_frame>Baseline,6 months,12 months</time_frame>
    <description>leg strength( Cybex),timed up and go,hand grip,chair stand,gait speed,quiet stance,postural stability( biodex),standing balance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Falls</measure>
    <time_frame>Baseline and every 3 months</time_frame>
    <description>questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function studies</measure>
    <time_frame>baseline and final test</time_frame>
    <description>FEV1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genotyping</measure>
    <time_frame>one time</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Molecular studies of peripheral leucocytes</measure>
    <time_frame>baseline and final test</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adult Depression Score</measure>
    <time_frame>baseline and 12 months</time_frame>
    <description>questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical Activity Scale form ( PASE)</measure>
    <time_frame>baseline,6 months,12 months</time_frame>
    <description>questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sun exposure</measure>
    <time_frame>baseline and every 3 months</time_frame>
    <description>sun exposure form and skin color evaluation by a reflective meter (SmartProbe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Basic metabolic panel</measure>
    <time_frame>baseline and every 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum 1,25 dihydroxyvitamin D</measure>
    <time_frame>baseline and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>baseline and 12 months</time_frame>
    <description>questionnaire</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">273</enrollment>
  <condition>Osteoporosis</condition>
  <condition>Aging</condition>
  <arm_group>
    <arm_group_label>vitamin D3 400 IU daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vitamin D3 400 IU daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vitamin D3 800 IU daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vitamin D3 800 IU daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vitamin D3 1600 IU daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vitamin D3 1600 IU daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vitamin D3 2400 IU daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vitamin D3 2400 IU daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vitamin D3 3200 IU daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vitamin D3 3200 IU daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vitamin D3 4000 IU daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vitamin D3 4000 IU daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vitamin D3 4800 IU daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vitamin D3 4800 IU daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>matched to vitamin D tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>Orally for one year</description>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_label>vitamin D3 1600 IU daily</arm_group_label>
    <arm_group_label>vitamin D3 2400 IU daily</arm_group_label>
    <arm_group_label>vitamin D3 3200 IU daily</arm_group_label>
    <arm_group_label>vitamin D3 400 IU daily</arm_group_label>
    <arm_group_label>vitamin D3 4000 IU daily</arm_group_label>
    <arm_group_label>vitamin D3 4800 IU daily</arm_group_label>
    <arm_group_label>vitamin D3 800 IU daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Calcium Citrate (Citracal)</intervention_name>
    <description>Orally for one year; dosage adjusted so that calcium intake is 1200-1400mg daily</description>
    <arm_group_label>vitamin D3 1600 IU daily</arm_group_label>
    <arm_group_label>vitamin D3 2400 IU daily</arm_group_label>
    <arm_group_label>vitamin D3 3200 IU daily</arm_group_label>
    <arm_group_label>vitamin D3 400 IU daily</arm_group_label>
    <arm_group_label>vitamin D3 4000 IU daily</arm_group_label>
    <arm_group_label>vitamin D3 4800 IU daily</arm_group_label>
    <arm_group_label>vitamin D3 800 IU daily</arm_group_label>
    <other_name>Citracal</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At least 7 years post-menopause&#xD;
&#xD;
          -  Serum 25OHD level 5 ng/ml to 20 ng/ml&#xD;
&#xD;
          -  BMI less than or equal to 40 kg/m2&#xD;
&#xD;
          -  Willing to discontinue multivitamins that contain vitamin D during the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cancer (except basal cell carcinoma) or terminal illness&#xD;
&#xD;
          -  Previous hip fracture&#xD;
&#xD;
          -  Hemiplegia (paralysis of one side of the body)&#xD;
&#xD;
          -  Uncontrolled type I diabetes or fasting blood sugar greater than 140 mg in type II&#xD;
&#xD;
          -  Kidney stones more than twice in a lifetime&#xD;
&#xD;
          -  Chronic renal failure&#xD;
&#xD;
          -  Evidence of chronic liver disease, including alcoholism&#xD;
&#xD;
          -  Physical conditions such as severe osteoarthritis, rheumatoid arthritis, heart failure&#xD;
             severe enough to prevent reasonable physical activity&#xD;
&#xD;
          -  Previous treatment with bisphosphonates (more that 3 months), PTH or PTH derivatives,&#xD;
             (e.g. Teriparatide or Fluoride) in the last 6 months&#xD;
&#xD;
          -  Previous treatment within the last 6 months with calcitonin or estrogen&#xD;
&#xD;
          -  Chronic high dose corticosteroid therapy (more than 10 mg per day) for over 6 months&#xD;
             and not within the last 6 months&#xD;
&#xD;
          -  Anticonvulsant therapy&#xD;
&#xD;
          -  High dose thiazide therapy (more than 37.5 mg)&#xD;
&#xD;
          -  24 hour urine calcium greater than 290 mg on 2 baseline tests&#xD;
&#xD;
          -  Serum calcium exceeding upper normal limit on 2 baseline tests&#xD;
&#xD;
          -  Bone Mineral Density T-score less than -3.0 for spine or hip&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>57 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J C Gallagher, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Creighton University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Creighton University Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gallagher JC, Kinyamu HK, Fowler SE, Dawson-Hughes B, Dalsky GP, Sherman SS. Calciotropic hormones and bone markers in the elderly. J Bone Miner Res. 1998 Mar;13(3):475-82.</citation>
    <PMID>9525348</PMID>
  </reference>
  <reference>
    <citation>Holick MF, Siris ES, Binkley N, Beard MK, Khan A, Katzer JT, Petruschke RA, Chen E, de Papp AE. Prevalence of Vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab. 2005 Jun;90(6):3215-24. Epub 2005 Mar 29.</citation>
    <PMID>15797954</PMID>
  </reference>
  <reference>
    <citation>Aloia JF, Talwar SA, Pollack S, Feuerman M, Yeh JK. Optimal vitamin D status and serum parathyroid hormone concentrations in African American women. Am J Clin Nutr. 2006 Sep;84(3):602-9.</citation>
    <PMID>16960175</PMID>
  </reference>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>May 10, 2007</study_first_submitted>
  <study_first_submitted_qc>May 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2007</study_first_posted>
  <last_update_submitted>March 11, 2016</last_update_submitted>
  <last_update_submitted_qc>March 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cholecalciferol</keyword>
  <keyword>vitamin D deficiency</keyword>
  <keyword>bone density</keyword>
  <keyword>dietary calcium</keyword>
  <keyword>hypercalcemia</keyword>
  <keyword>hypercalciuria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

